|
GB8529014D0
(en)
|
1985-11-25 |
1986-01-02 |
Biogen Nv |
Enhanced secretion of heterologous proteins
|
|
EP0272253A4
(en)
|
1986-03-07 |
1990-02-05 |
Massachusetts Inst Technology |
METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US5080891A
(en)
|
1987-08-03 |
1992-01-14 |
Ddi Pharmaceuticals, Inc. |
Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
US5571714A
(en)
|
1988-12-22 |
1996-11-05 |
Celtrix Pharmaceuticals, Inc. |
Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
|
|
US5198346A
(en)
|
1989-01-06 |
1993-03-30 |
Protein Engineering Corp. |
Generation and selection of novel DNA-binding proteins and polypeptides
|
|
US5096815A
(en)
|
1989-01-06 |
1992-03-17 |
Protein Engineering Corporation |
Generation and selection of novel dna-binding proteins and polypeptides
|
|
WO1991019513A1
(en)
|
1990-06-20 |
1991-12-26 |
Bristol-Myers Squibb Company |
METHODS OF MODULATING BLOOD PRESSURE USING TGF-β AND ANTAGONISTS THEREOF
|
|
GB9106678D0
(en)
|
1991-03-28 |
1991-05-15 |
Ferguson Mark W J |
Wound healing
|
|
DE69232986T2
(de)
|
1991-10-31 |
2003-12-11 |
Whitehead Biomedical Inst |
TGF-BETA TYP III REZEPTOR, DAFüR KODIERENDE CDNS UND DEREN VERWENDUNG
|
|
US6008011A
(en)
|
1991-10-31 |
1999-12-28 |
Whitehead Institute For Biomedical Research |
TGF-β type II receptor cDNAs
|
|
US5543143A
(en)
|
1992-03-06 |
1996-08-06 |
Corixa Corporation |
Method for activating macrophages/monocytes
|
|
ES2174868T3
(es)
|
1992-10-29 |
2002-11-16 |
Celtrix Pharma |
Fragmento del receptor de fijacion a tgf-beta tipoii como agente terapeutico.
|
|
US5677196A
(en)
|
1993-05-18 |
1997-10-14 |
University Of Utah Research Foundation |
Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
|
|
US5885573A
(en)
|
1993-06-01 |
1999-03-23 |
Arch Development Corporation |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
|
WO1994029351A2
(en)
|
1993-06-16 |
1994-12-22 |
Celltech Limited |
Antibodies
|
|
AU701623B2
(en)
|
1993-10-14 |
1999-02-04 |
President And Fellows Of Harvard College |
Method of inducing and maintaining neuronal cells
|
|
US5470952A
(en)
|
1993-10-20 |
1995-11-28 |
Regeneron Pharmaceuticals, Inc. |
CNTF and IL-6 antagonists
|
|
US5525490A
(en)
|
1994-03-29 |
1996-06-11 |
Onyx Pharmaceuticals, Inc. |
Reverse two-hybrid method
|
|
US5541087A
(en)
|
1994-09-14 |
1996-07-30 |
Fuji Immunopharmaceuticals Corporation |
Expression and export technology of proteins as immunofusins
|
|
US5814565A
(en)
|
1995-02-23 |
1998-09-29 |
University Of Utah Research Foundation |
Integrated optic waveguide immunosensor
|
|
US5866323A
(en)
|
1995-04-07 |
1999-02-02 |
Case Western Reserve University |
Cancer diagnosis prognosis and therapy based on mutation of receptors for transforming growth factor β and homologous growth controlling factors
|
|
WO1996032503A1
(en)
|
1995-04-11 |
1996-10-17 |
The General Hospital Corporation |
Reverse two-hybrid systems
|
|
US6423501B2
(en)
|
1996-12-13 |
2002-07-23 |
Beth Israel Deaconess Medical Center |
Calcium-independent negative regulation by CD81 of receptor signaling
|
|
WO1998048024A1
(en)
|
1997-04-18 |
1998-10-29 |
Biogen, Inc. |
Type ii tgf-beta receptor/immunoglobulin constant region fusion proteins
|
|
AU7467898A
(en)
|
1997-04-21 |
1998-11-13 |
Arch Development Corporation |
Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial cr signal and induce clonal anergy
|
|
US6294350B1
(en)
|
1997-06-05 |
2001-09-25 |
Dalhousie University |
Methods for treating fibroproliferative diseases
|
|
MY131805A
(en)
|
1997-09-18 |
2007-09-28 |
Biogen Idec Inc |
Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis.
|
|
ATE375365T1
(de)
|
1998-04-02 |
2007-10-15 |
Genentech Inc |
Antikörper varianten und fragmente davon
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
AU4572899A
(en)
|
1998-06-16 |
2000-01-05 |
Biogen, Inc. |
Variant type ii tgf-beta receptor fusion proteins and methods
|
|
ES2146552B1
(es)
|
1998-11-24 |
2001-04-16 |
Inst Cientifico Tecnol Navarra |
Peptidos inhibidores de tgf/31
|
|
JP2004502644A
(ja)
|
2000-03-09 |
2004-01-29 |
ジェンザイム、コーポレーション |
腎機能の喪失を治療または予防するためのＴＧＦ−β拮抗薬の使用
|
|
WO2001073128A1
(en)
|
2000-03-24 |
2001-10-04 |
Dzgenes, Llc |
DIAGNOSTIC POLYMORPHISMS OF TGF-β-RII PROMOTER
|
|
US20030028905A1
(en)
|
2001-07-31 |
2003-02-06 |
Petra Knaus |
Mutant forms of the TGF-beta type II receptor which bind all TGF-beta isoforms
|
|
JP4564261B2
(ja)
|
2002-01-22 |
2010-10-20 |
ジェンザイム、コーポレーション |
慢性的移植片拒絶反応の治療と予防のためのＴＧＦ−β拮抗薬の使用
|
|
US7919084B2
(en)
|
2002-06-17 |
2011-04-05 |
St. Vincent's Hospital Sydney Limited |
Methods of diagnosis, prognosis and treatment of cardiovascular disease
|
|
JP2006512369A
(ja)
|
2002-12-19 |
2006-04-13 |
サイオス・インコーポレーテツド |
ＴＧＦ−β阻害剤を用いる肥満症および関連症状の処置
|
|
US20060286105A1
(en)
|
2003-04-30 |
2006-12-21 |
Steven Ledbetter |
Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency
|
|
WO2005019258A2
(en)
|
2003-08-11 |
2005-03-03 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
US20060229266A1
(en)
|
2003-08-13 |
2006-10-12 |
Kumar Nalin M |
Silencing of tgf-beta receptor type II expression by sirna
|
|
EP1658060A2
(en)
|
2003-08-22 |
2006-05-24 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Methods of treating copd and pulmonary hypertension
|
|
WO2005113585A2
(en)
|
2004-05-20 |
2005-12-01 |
Acceleron Pharma Inc. |
Modified tgf-beta superfamily polypeptides
|
|
US7786261B2
(en)
|
2004-09-02 |
2010-08-31 |
National Research Council Of Canada |
Coiled-coil fusion proteins comprising cell receptor domains
|
|
BRPI0515588A
(pt)
|
2004-09-22 |
2008-07-29 |
Genzyme Corp |
uso de antagonistas de tgf-beta para limitar a nefrotoxicidade de agentes imunossupressivos
|
|
US7795389B2
(en)
|
2004-09-28 |
2010-09-14 |
The Board Of Regents Of The University Of Texas System |
Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
|
|
JP5481028B2
(ja)
|
2004-10-13 |
2014-04-23 |
ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション |
ウイルス関連リンパ増殖性障害を処置または予防するための方法
|
|
CA2930677A1
(en)
|
2005-02-08 |
2006-08-17 |
Genzyme Corporation |
Antibodies to tgfbeta
|
|
JP5342834B2
(ja)
|
2008-09-05 |
2013-11-13 |
日東電工株式会社 |
骨髄線維症処置剤
|
|
ITMI20060181A1
(it)
|
2006-02-03 |
2007-08-04 |
Univ Padova |
Modulatori del tgf-b e loro uso
|
|
EP1998810A4
(en)
|
2006-03-13 |
2009-09-02 |
Univ Johns Hopkins |
INCREASE OF ENDOTHELIAL THROMBORESISTENTEN
|
|
JP2009539842A
(ja)
|
2006-06-05 |
2009-11-19 |
ノバルティス アクチエンゲゼルシャフト |
副甲状腺関連障害の処置におけるＴＧＦ−βアンタゴニストの使用
|
|
HUE035575T2
(en)
|
2006-10-03 |
2018-05-28 |
Genzyme Corp |
Use of TGF-beta antagonists to treat children at risk of developing bronchopulmonary dysplasia
|
|
EP2140005B1
(en)
|
2007-03-19 |
2013-12-11 |
National Research Council of Canada |
Fusion proteins comprising two tgf-beta binding domains
|
|
JP2010529859A
(ja)
|
2007-06-15 |
2010-09-02 |
ジェンザイム、コーポレーション |
ＴＧＦ−βＩＩ型受容体の２つのＴＧＦ−β結合ドメインを含有する融合タンパク質
|
|
BRPI0815572A2
(pt)
|
2007-08-22 |
2015-02-18 |
Irm Llc |
Compostos e composições como inibidores de quinases
|
|
JP2011509676A
(ja)
|
2008-01-18 |
2011-03-31 |
ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド |
ヒトＴｈ１７細胞の選択的分化、同定および調節
|
|
US20110104121A1
(en)
|
2008-05-21 |
2011-05-05 |
Wira Charles R |
Female Reproductive Tract and Anal Prophylaxes
|
|
WO2009152610A1
(en)
|
2008-06-20 |
2009-12-23 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof
|
|
KR20110044992A
(ko)
|
2008-07-02 |
2011-05-03 |
이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 |
ＴＧＦ-β 길항제 다중-표적 결합 단백질
|
|
CA2737271C
(en)
|
2008-09-17 |
2020-06-23 |
National Research Council Of Canada |
Hetero-multivalent binding agents for members of the tgf.beta. superfamily
|
|
US20120010178A1
(en)
|
2008-10-21 |
2012-01-12 |
President And Fellows Of Harvard College |
Methods and compounds for treatment of neurodegenerative disorders
|
|
EP2387412A4
(en)
|
2009-01-13 |
2013-04-03 |
Acceleron Pharma Inc |
METHODS FOR INCREASING ADIPONECTIN
|
|
WO2010129515A1
(en)
|
2009-05-08 |
2010-11-11 |
The United Satates Of America As Represented By The Secretary, Department Of Health & Human Services |
Modulation of the tgf-beta and pi3k/akt pathways in the diagnosis and treatment of squamous cell carcinoma
|
|
WO2011088148A1
(en)
|
2010-01-12 |
2011-07-21 |
Isis Pharmaceuticals, Inc. |
Modulation of transforming growth factor-beta 1 expression
|
|
IL300733A
(en)
|
2010-03-05 |
2023-04-01 |
Univ Johns Hopkins |
Compositions and methods for antibodies and fusion proteins targeting immune modulation
|
|
CN101852804B
(zh)
|
2010-03-29 |
2013-06-12 |
中国医学科学院病原生物学研究所 |
Gdf15蛋白的抗体的新用途
|
|
US8080568B1
(en)
|
2010-06-29 |
2011-12-20 |
Ewha University - Industry Collaboration Foundation |
2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
|
|
NZ624382A
(en)
|
2010-09-01 |
2015-05-29 |
Genzyme Corp |
Treatment of myocardial infarction using tgf - beta antagonists
|
|
US20130287688A1
(en)
|
2010-11-18 |
2013-10-31 |
Xtuit Pharmaceuticals, Inc. |
Novel compositions and uses of anti-hypertension agents for cancer therapy
|
|
US8800906B2
(en)
|
2010-12-27 |
2014-08-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Use of transforming growth factor-beta neutralizing antibodies and fusion proteins thereof in treating pain
|
|
PE20140982A1
(es)
|
2011-01-06 |
2014-08-22 |
Glaxo Group Ltd |
Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta
|
|
TWI631136B
(zh)
*
|
2011-04-19 |
2018-08-01 |
莫瑞麥克製藥公司 |
單特異性及雙特異性抗ｉｇｆ－１ｒ及抗ｅｒｂｂ３抗體
|
|
CN103781798B
(zh)
|
2011-04-20 |
2018-03-13 |
阿塞勒隆制药公司 |
内皮糖蛋白多肽及其用途
|
|
CN102850458B
(zh)
|
2011-06-28 |
2014-10-01 |
华博生物医药技术（上海）有限公司 |
新型重组双功能融合蛋白及其制法和用途
|
|
WO2013012648A1
(en)
|
2011-07-15 |
2013-01-24 |
Emory University |
Gdf15 in diagnostic and therapeutic applications
|
|
EP3530275A1
(en)
|
2011-08-01 |
2019-08-28 |
Tufts Medical Center, Inc. |
Treatment of heart failure and related conditions
|
|
AU2013202269A1
(en)
|
2011-10-26 |
2013-05-16 |
Howard Florey Institute Of Experimental Physiology And Medicine |
Compositions and methods for the treatment of fibrosis and fibrotic diseases
|
|
EP4219536A3
(en)
|
2012-04-30 |
2023-08-23 |
Biocon Limited |
Targeted/immunomodulatory fusion proteins and methods for making same
|
|
CA2873745A1
(en)
|
2012-05-16 |
2013-11-21 |
Aadigen, Llc |
Multi-target modulation for treating fibrosis and inflammatory conditions
|
|
SG10201707021RA
(en)
|
2013-03-11 |
2017-10-30 |
Genzyme Corp |
Engineered anti-tgf-beta antibodies and antigen-binding fragments
|
|
RU2662991C2
(ru)
|
2013-03-12 |
2018-07-31 |
Биокон Лтд. |
Слитые иммуномодулирующие белки и способы их получения
|
|
US10584158B2
(en)
|
2013-04-17 |
2020-03-10 |
Baylor College Of Medicine |
Immunosuppressive TGF-β signal converter
|
|
WO2015027082A1
(en)
|
2013-08-22 |
2015-02-26 |
Acceleron Pharma, Inc. |
Tgf-beta receptor type ii variants and uses thereof
|
|
ES2778201T3
(es)
|
2013-11-21 |
2020-08-10 |
Brigham & Womens Hospital Inc |
Composiciones y métodos para tratar la hipertensión pulmonar
|
|
JP6731346B2
(ja)
|
2014-02-10 |
2020-07-29 |
メルク パテント ゲーエムベーハー |
標的ＴＧＦβ阻害
|
|
JP6773563B2
(ja)
|
2014-05-18 |
2020-10-21 |
ザ チルドレンズ メディカル センター コーポレーション |
エキソソームに関連する方法および組成物
|
|
EP3154559B1
(en)
|
2014-06-13 |
2021-09-01 |
Novartis AG |
Use of serelaxin to reduce gdf-15
|
|
AU2015296037B2
(en)
|
2014-08-01 |
2021-04-29 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions relating to treatment of pulmonary arterial hypertension
|
|
JP6631865B2
(ja)
*
|
2014-08-11 |
2020-01-15 |
日本化薬株式会社 |
ＴＧＦβ阻害機能を持つキメラタンパク質
|
|
KR20180002661A
(ko)
|
2015-04-06 |
2018-01-08 |
악셀레론 파마 인코포레이티드 |
ALK7:ActRIIB 이형다합체와 이의 용도
|
|
CN107849114B
(zh)
*
|
2015-04-06 |
2021-08-20 |
阿塞勒隆制药公司 |
单臂i型和ii型受体融合蛋白和其用途
|
|
CA2994413A1
(en)
*
|
2015-08-04 |
2017-02-09 |
Acceleron Pharma, Inc. |
Methods for treating myeloproliferative disorders
|
|
US20200231652A1
(en)
|
2015-08-31 |
2020-07-23 |
National Research Council Of Canada |
Tgf-b-receptor ectodomain fusion molecules and uses thereof
|
|
WO2017134592A1
(en)
*
|
2016-02-03 |
2017-08-10 |
Biocon Limited |
Anti-cd20/immunomodulatory fusion proteins and methods for making same
|
|
CA3031168A1
(en)
|
2016-08-12 |
2018-02-15 |
Merck Patent Gmbh |
Combination therapy for cancer
|
|
KR20240014617A
(ko)
|
2016-09-27 |
2024-02-01 |
에피센트알엑스, 인코포레이티드 |
면역조정 융합 단백질
|
|
KR20190102059A
(ko)
|
2017-01-07 |
2019-09-02 |
메르크 파텐트 게엠베하 |
표적화된 TGF-β 억제를 위한 투약 레지멘 및 투여 형태
|
|
EP3589663A4
(en)
|
2017-03-02 |
2020-10-21 |
National Research Council of Canada |
TGF-ß RECEPTOR EECTODOMAN FUSION MOLECULES AND USES THEREOF
|
|
AU2019216761A1
(en)
|
2018-02-09 |
2020-09-03 |
Acceleron Pharma Inc. |
Methods for treating heterotopic ossification
|